Geneva, Switzerland, and Paris, France, October 28, 2017 – 11:00 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today post hoc analyses of 6-month data from the CHANGE-MS Phase 2b study of GNb ...
Geneva, Switzerland, 11 September 2017 – 07:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that data supporting the ...
Geneva, Switzerland, and Paris, France, 28 August 2017 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today 6-month results from the 12-month CHANGE-MS Phase 2b study of three doses ...
Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that data in multiple preclinical models showed that GKT831, the Company’s NOX ...
Archamps (France) and Geneva (Switzerland), June 28th, 2017 at 6:00pm CEST. Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today ...
Archamps (France) and Geneva (switzerland), June 27th, 2017 at 6:00 pm CEST Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX.pa), a biopharmaceutical company and the leader in NOX therapies, announced to ...
